Fierce Pharma

NOVEMBER 13, 2024

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. | As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term, according to a new loss of exclusivity report from Leerink Partners.

277

277

pharmaphorum

NOVEMBER 13, 2024

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US.The FDA has approved PTC's eladocagene exuparvovec – known as Upstaza in Europe – under the Kebilidi trade name in the US. It is cleared for both children and adults with AADC (aromatic L-amino acid decarboxylase) deficiency, a fatal disease that causes severe disability and suffering from the first months of life.

FDA 95

FDA Patients 95

Fierce Pharma

NOVEMBER 13, 2024

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1), AstraZeneca is touting a trial result that could allow the company and | Four years after scoring an FDA approval to treat children with NF1, AstraZeneca says its Merck-partnered Koselugo has shown promise in adults.

FDA 276

FDA 276

pharmaphorum

NOVEMBER 13, 2024

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM).The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside Bristol-Myers Squibb/Celgene's Imnovid (pomalidomide) and dexamethasone (Isa-Pd) for relapsed RRMM.

98

98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Fierce Pharma

NOVEMBER 13, 2024

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward layoffs and scrap further development of its seizure med Ztalmy. | The company last month opted to end development of its flagship seizure drug while exploring "strategic alternatives" to maximize shareholder value ahead of a planned FDA meeting.

FDA 161

FDA Pharmaceutical 161

MedCity News

NOVEMBER 13, 2024

Are you a self-insured employer looking for ways to reduce healthcare spend? Join us for a webinar on December 11 in which HR executives will share their insights. The post Where Can Self-Insured Employers Look to Find Healthcare Savings? appeared first on MedCity News.

Insurance 97

Insurance Healthcare Healthcare 97

MedCity News

NOVEMBER 13, 2024

Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery. The post The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery appeared first on MedCity News.

Medical 92

Medical Patients Pharmaceutical Physicians 92

Pharmaceutical Technology

NOVEMBER 13, 2024

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported.

78

78

MedCity News

NOVEMBER 13, 2024

There has been a surge in digital mental health solutions, making it difficult to know which ones are effective. One Optum exec weighed in on how she’s managing this challenge. The post How One Optum Exec Is Handling the Influx of Digital Mental Health Solutions appeared first on MedCity News.

Management 78

Management 78

pharmaphorum

NOVEMBER 13, 2024

London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US, says MedCity report

67

67

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

NOVEMBER 13, 2024

High labor costs remain an ongoing problem threatening providers’ bottom lines, according to new data from Kaufman Hall. The research revealed that medical groups’ median investment in each employed physician has reached more than $300,000 for the first time. The post High Labor Costs Continue to Plague Providers, Data Shows appeared first on MedCity News.

Physicians 68

Physicians Medical 68

pharmaphorum

NOVEMBER 13, 2024

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density

Safety 69

Safety 69

MedCity News

NOVEMBER 13, 2024

Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs. The post Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court appeared first on MedCity News.

Medicine 64

Medicine Patients Biopharma Pharma 64

European Pharmaceutical Review

NOVEMBER 13, 2024

New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis (PrEP) had high efficacy and safety in a diverse group of participants. This data provides the first in-depth insight into full results of Gilead Sciences pivotal Phase III PURPOSE 2 trial. In the oral PrEP study group, adherence to the small molecule injectable HIV-1 capsid inhibitor and placebo injections was 91.0 percent with on-time injections at week 26, the results showed.

Food and Drug Administration 59

Food and Drug Administration Pharmacology Medicine Food 59

Advertisement

PharmExec

NOVEMBER 13, 2024

Results from the Phase III KOMET trial found that Koselugo demonstrated a statistically significant objective response rate compared to placebo treating plexiform neurofibromas.

52

52

Contrarian Sales Techniques

NOVEMBER 13, 2024

"The best way to predict the future is to create it." - Philip Kotler When marketing legend Philip Kotler said these words, he could have been speaking directly to Malaysian businesses facing the winds of change. In a world where prediction seems impossible, Kotler suggests something revolutionary: don't just prepare for the future – shape it. Consider the fascinating story of Proton's evolution.

Marketing 52

Marketing Food Competition 52

Evolve Your Success

NOVEMBER 13, 2024

Join me for a fascinating conversation with Greg Olson, a seasoned expert from Medtronic, as we uncover the intricate world of medical sales, specifically focusing on cardiac rhythm management (CRM). Greg, having devoted 25 years to the company, shares his invaluable insights as a Senior District Service Manager, leading a dedicated team of clinical specialists.

Management 52

Management Medical sales Sales Medical 52

Spotio

NOVEMBER 13, 2024

In today’s unpredictable market, field sales teams face rising competition, economic uncertainty, and evolving buyer demands. SPOTIO’s Fifth Edition State of Field Sales Report reveals key insights and actionable strategies that empower field sales professionals to overcome these challenges and consistently achieve their targets. Based on over 500 responses from sales executives, managers, and reps across industries, this report offers a deep dive into : Deal Trends & Challenges – Gain an ed

Sales 52

Sales Competition Management Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Commerce

NOVEMBER 13, 2024

The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.

Distribution 52

Distribution Marketing 52

PharmExec

NOVEMBER 13, 2024

As part of the acquisition, BioNTech will obtain the rights to BNT327/PM8002, a bispecific antibody that targets PD-L1-low and -negative tumors that often resist checkpoint inhibitors.

52

52

PharmaTech

NOVEMBER 13, 2024

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

Management 52

Management Manufacturing 52

pharmaphorum

NOVEMBER 13, 2024

It's been over a year since Babylon Health – once the darling of the UK digital health sector – foundered into bankruptcy and, in the meantime, former CEO Ali Parsa has not been idle. In a return to social media after a protracted absence, Parsa has ended speculation about his next move by revealing new healthtech venture Quadrivia, which was set up to develop Qu, described as a digital personal assistant "for clinicians, by clinicians.

Media 52

Media 52

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

PharmaTech

NOVEMBER 13, 2024

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Manufacturing 52

Manufacturing 52

Contrarian Sales Techniques

NOVEMBER 13, 2024

"The aim of marketing is to know and understand the customer so well the product or service fits them and sells itself." - Peter Drucker You know those moments when you read something and think, "Well, that just makes perfect sense!"? That's exactly what happened when Peter Drucker dropped this wisdom bomb back in the 1950s. At a time when businesses were obsessed with churning out products and hoping customers would buy them, Drucker came along and essentially said, "Hey, maybe we're doing this

Marketing 52

Marketing 52

pharmaphorum

NOVEMBER 13, 2024

BioNTech buys Biotheus and its Keytruda rival for $950m Phil.

89

89

PharmaVoice

NOVEMBER 13, 2024

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

Marketing 96

Marketing Pharma Patients 96

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmaTimes

NOVEMBER 13, 2024

New long-term partnership to address neurological disorder treatments

80

80

Pharmaceutical Technology

NOVEMBER 13, 2024

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia.

Patients 52

Patients 52

Pharmaceutical Commerce

NOVEMBER 13, 2024

A cross-sectional study uses epidemiological patterns to investigate these disparities, while also predicting the potential shift of these patterns by 2050.

52

52

PharmExec

NOVEMBER 13, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52

Pharma 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales